Quick Answer
Telomir Pharmaceuticals, Inc. reported Stockholders Equity of $5.91 million for fiscal year 2025.
Telomir Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.91M | +819.6% |
| 2024 | $643.0K | -81.3% |
| 2023 | $3.44M | +466.8% |
| 2022 | -$937.3K | -578.5% |
| 2021 | -$138.1K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.98M | +1478.8% | +1350.3% |
| June 30, 2025 | $481.2K | -70.4% | +398.7% |
| March 31, 2025 | -$161.1K | -105.3% | -125.1% |
| December 31, 2024 | $643.0K | -81.3% | +45.5% |
| September 30, 2024 | $442.1K | -79.7% | -72.8% |
| June 30, 2024 | $1.63M | -58.2% | -46.0% |
| March 31, 2024 | $3.02M | +691.2% | -12.3% |
| December 31, 2023 | $3.44M | +466.8% | +57.9% |
- Telomir Pharmaceuticals, Inc. showed an increase of +819.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Telomir Pharmaceuticals, Inc.’s stockholders equity has grown by 4381.0% (from -$138.1 thousand to $5.91 million).
- The most recent figure is from Telomir Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: